0000899243-16-028314.txt : 20160831 0000899243-16-028314.hdr.sgml : 20160831 20160831182517 ACCESSION NUMBER: 0000899243-16-028314 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160829 FILED AS OF DATE: 20160831 DATE AS OF CHANGE: 20160831 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sagent Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001369786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1901 NORTH ROSELLE ROAD, SUITE 700 CITY: SCHAUMBURG STATE: IL ZIP: 60195 BUSINESS PHONE: 847-908-1604 MAIL ADDRESS: STREET 1: 1901 NORTH ROSELLE ROAD, SUITE 700 CITY: SCHAUMBURG STATE: IL ZIP: 60195 FORMER COMPANY: FORMER CONFORMED NAME: Sagent Holding Co. DATE OF NAME CHANGE: 20090529 FORMER COMPANY: FORMER CONFORMED NAME: NHS PHARMACEUTICALS DATE OF NAME CHANGE: 20060720 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: OBERMAN ALLAN CENTRAL INDEX KEY: 0001656585 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35144 FILM NUMBER: 161864194 MAIL ADDRESS: STREET 1: C/O SAGENT PHARMACEUTICALS, INC. STREET 2: 1901 NORTH ROSELLE ROAD, SUITE 700 CITY: SCHAUMBURG STATE: IL ZIP: 60195 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-08-29 1 0001369786 Sagent Pharmaceuticals, Inc. SGNT 0001656585 OBERMAN ALLAN C/O SAGENT PHARMACEUTICALS, INC. 1901 NORTH ROSELLE ROAD, SUITE 700 SCHAUMBURG IL 60195 1 1 0 0 Chief Executive Officer Common Stock 2016-08-29 4 D 0 9459 21.75 D 92527 D Common Stock 2016-08-29 4 D 0 92527 21.75 D 0 D Stock Option to Buy 14.61 2016-08-29 4 D 0 108696 7.14 D 2026-02-22 Common Stock 108696 0 D Pursuant to the Agreement and Plan of Merger by and among Nichi-Iko Pharmaceutical Co. Ltd., Shepard Vision, Inc. and Sagent Pharmaceuticals, Inc. (the "Merger Agreement"), these shares were canceled and converted into the right to receive $21.75 per share in cash, without interest, less any applicable withholding taxes (the "Merger Consideration"). Pursuant to the Merger Agreement, these restricted shares were canceled and converted into the right to receive the Merger Consideration. Represents the disposition of options, which provided for vesting in four equal installments beginning February 22, 2017. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $7.14 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Merger Consideration. /s/ Allan Oberman 2016-08-31